Why Altimmune, Inc.’s (ALT) Stock Is Down 5.54%
As of Friday, July 31, Altimmune, Inc.’s ALT share price has dipped by 5.54%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Commentary & Analysis
Why Altimmune, Inc.’s (ALT) Stock Is Up 8.06%
As of Wednesday, July 01, Altimmune, Inc.’s ALT share price has surged by 8.06%, which has investors questioning if this is right time to sell.Michael Rose
Why Altimmune, Inc.’s (ALT) Stock Is Up 8.89%
As of Monday, June 22, Altimmune, Inc.’s ALT share price has surged by 8.89%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Altimmune, Inc.’s (ALT) Stock Is Down 5.67%
As of Thursday, May 07, Altimmune, Inc.’s ALT share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Altimmune, Inc.’s (ALT) Stock Is Up 5.88%
As of Monday, May 04, Altimmune, Inc.’s ALT share price has surged by 5.88%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ALT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $552.3 | $252.6 | 39% |
|
| Shares Out (Mil) | 124.5 | 52.3 | 67% |
|
| Institutional Ownership | 99.0% | 92.1% | 84% |
|
| Float (Mil) | 164.2 | 40.2 | 71% |
|
| Beta | 0.17 | 0.95 | 11% |
|
| Avg Daily Volume (000s) | 4,925 | 455 | 92% |
|
| Price Change (52-week) |
(22.2%) | 52.9% | 29% |
|
| Growth | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.4%) | (9.9%) | 27% |
|
| EPS (5yr) | 12.2% | 16.0% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.6%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.125) | ($0.573) | ($0.692) | |
| Month Ago EPS | ($0.157) | ($0.709) | ($0.859) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.249) | ($1.111) | ($1.320) | |
| Year/Year Chg | (30.9%) | (42.7%) | (18.5%) | |
| Financials | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($91) | ($43) | 11% |
|
| EPS (TTM) | ($0.908) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($72) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $49 | $5 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $36 | $5 | 36% |
|
| Enterprise Value (Q1) (Mil) | $272 | $180 | 29% |
|
| Valuation | ALT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.30 | 2.56 | 33% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ALT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (37.0%) | (49.8%) | 15% |
|
| ROE | (42.7%) | (55.5%) | 17% |
|
| Liabilities to Assets | 15.4% | 30.3% | 9% |
|
| F-Score | 4 | 3 | 34% |
|
Altimmune, Inc. did not pass any screens on 7/31/2026.
